FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107702> ?p ?o ?g. }

• W4310107702 endingPage "7765" @default.
• W4310107702 startingPage "7763" @default.
• W4310107702 abstract "Background: Hematopoietic stem cell transplant (HCT) represents the most effective mean to achieve cure for children, adolescents and young adults with relapsed or refractory (R/R) B-ALL. Among the several disease-specific and transplant-specific characteristics evaluated so far, achievement of minimal residual disease (MRD) negative complete remission (CR) prior to HCT is the strongest independent prognostic factor of post-HCT outcome. Antigen directed therapies (ADT) such as blinatumomab, inotuzumab ozogamicin and chimeric antigen receptor (CAR) T-cell are very effective at inducing MRD-negative remission and offer an alternative approach for disease control in patients with chemo-resistant disease. We hypothesized that ADT may provide a more durable disease control and lesser morbidity than conventional chemotherapy (CT) and therefore we sought to explore whether the type of treatment (ADT or CT) adopted to achieve MRD negative CR prior to HCT, impacts post-HCT outcomes. Patients and methods: This is a retrospective, multi-institutional cohort study of patients (pts) with R/R B-ALL who received an allogeneic HCT in MRD negative CR between 2010-2021. Patients were eligible if they were ≤30 years at time of diagnosis of R/R B-ALL, had received either CT or ADT (blinatumomab, CAR T-cell, inotuzumab ozogamicin with or without preceding chemotherapy) for the treatment of R/R B-ALL and had achieved MRD negative CR (<0.01% blasts by flow cytometry) prior to HCT. Patients with isolated extramedullary relapse or acute leukemia of ambiguous lineage or history of prior HCT were excluded. Patients were categorized as being in the CT or ADT group based on whether they received conventional CT or ADT as last cycle that led to MRD negativity prior to HCT. The primary objective of the study was to compare the EFS, OS and treatment related mortality (TRM) from time of transplant according to the therapy (ADT vs. CT) received pre-HCT. Kaplan-Meier or Aalen-Johansen estimates were used to estimate survival rates and curves were compared using logrank or Gray's tests. Results: Seventy-six pts from 7 centers met eligibility criteria; 38 pts (50.0%) received ADT and 38 pts (50.0%) received chemotherapy as last cycle prior to HCT. Demographic, disease and treatment characteristics are summarized in Table 1; notably, more pts in the ADT group had refractory leukemia and more pts had received ≥4 cycles of therapy before achieving MRD negative remission in the ADT group than in the CT group. The 5-yr. EFS and OS for the entire cohort were 53% and 67%, respectively. EFS was superior in the ADT group compared to the CT group (5-yr. EFS 64% vs. 42%, p=0.04; Figure 1). OS was also superior in the ADT group (85% vs. 47%, p=0.0008; Figure 1). In a univariable and multivariable prognostic model for OS that included age, race, having relapsed or refractory disease and CT or ADT as pre-HCT therapy, pre-HCT therapy was the only significant prognostic factor (p<0.001); in a similar model for EFS, pre-HCT therapy was the only significant prognostic factor in the univariable analysis (p=0.04) but not in the multivariable analysis. There was no difference in the incidence of acute GVHD, rate of immune reconstitution at day 100, time to engraftment and cumulative incidence of relapse between the two groups. However, the CT group appeared to have a higher rate of both TRM (33.0% vs. 8%, p=0.01) and relapse related mortality, although not significant for the latter (19% vs. 7% p=0.12). Conclusion: This multicenter study shows that having received ADT prior to HCT may be beneficial when compared to conventional chemotherapy for patients with R/R B-ALL who receive a HCT in MRD negative CR. Patients who received ADT experienced a superior EFS and OS primarily due to a significantly lower TRM, despite having received more cycles of therapy prior to proceeding to HCT. There was no difference in the relapse rate among the two groups further supporting the notion that MRD negative CR is the single most important predictor of post-HCT relapse. Further analysis is ongoing to identify specific factors that could explain the difference in post-HCT mortality among the 2 groups. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310107702 created "2022-11-30" @default.
• W4310107702 creator A5000086021 @default.
• W4310107702 creator A5005741602 @default.
• W4310107702 creator A5008040424 @default.
• W4310107702 creator A5009657865 @default.
• W4310107702 creator A5016775524 @default.
• W4310107702 creator A5018962418 @default.
• W4310107702 creator A5019273318 @default.
• W4310107702 creator A5019803188 @default.
• W4310107702 creator A5021295013 @default.
• W4310107702 creator A5024573751 @default.
• W4310107702 creator A5024767399 @default.
• W4310107702 creator A5026131694 @default.
• W4310107702 creator A5028110540 @default.
• W4310107702 creator A5037614274 @default.
• W4310107702 creator A5048379858 @default.
• W4310107702 creator A5048733835 @default.
• W4310107702 creator A5051912868 @default.
• W4310107702 creator A5055001531 @default.
• W4310107702 creator A5056285544 @default.
• W4310107702 creator A5056434644 @default.
• W4310107702 creator A5065852881 @default.
• W4310107702 creator A5075183737 @default.
• W4310107702 creator A5087051156 @default.
• W4310107702 creator A5091554825 @default.
• W4310107702 date "2022-11-15" @default.
• W4310107702 modified "2023-09-30" @default.
• W4310107702 title "Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL" @default.
• W4310107702 doi "https://doi.org/10.1182/blood-2022-160272" @default.
• W4310107702 hasPublicationYear "2022" @default.
• W4310107702 type Work @default.
• W4310107702 citedByCount "0" @default.
• W4310107702 crossrefType "journal-article" @default.
• W4310107702 hasAuthorship W4310107702A5000086021 @default.
• W4310107702 hasAuthorship W4310107702A5005741602 @default.
• W4310107702 hasAuthorship W4310107702A5008040424 @default.
• W4310107702 hasAuthorship W4310107702A5009657865 @default.
• W4310107702 hasAuthorship W4310107702A5016775524 @default.
• W4310107702 hasAuthorship W4310107702A5018962418 @default.
• W4310107702 hasAuthorship W4310107702A5019273318 @default.
• W4310107702 hasAuthorship W4310107702A5019803188 @default.
• W4310107702 hasAuthorship W4310107702A5021295013 @default.
• W4310107702 hasAuthorship W4310107702A5024573751 @default.
• W4310107702 hasAuthorship W4310107702A5024767399 @default.
• W4310107702 hasAuthorship W4310107702A5026131694 @default.
• W4310107702 hasAuthorship W4310107702A5028110540 @default.
• W4310107702 hasAuthorship W4310107702A5037614274 @default.
• W4310107702 hasAuthorship W4310107702A5048379858 @default.
• W4310107702 hasAuthorship W4310107702A5048733835 @default.
• W4310107702 hasAuthorship W4310107702A5051912868 @default.
• W4310107702 hasAuthorship W4310107702A5055001531 @default.
• W4310107702 hasAuthorship W4310107702A5056285544 @default.
• W4310107702 hasAuthorship W4310107702A5056434644 @default.
• W4310107702 hasAuthorship W4310107702A5065852881 @default.
• W4310107702 hasAuthorship W4310107702A5075183737 @default.
• W4310107702 hasAuthorship W4310107702A5087051156 @default.
• W4310107702 hasAuthorship W4310107702A5091554825 @default.
• W4310107702 hasConcept C121332964 @default.
• W4310107702 hasConcept C126322002 @default.
• W4310107702 hasConcept C142424586 @default.
• W4310107702 hasConcept C143998085 @default.
• W4310107702 hasConcept C2776694085 @default.
• W4310107702 hasConcept C2777408962 @default.
• W4310107702 hasConcept C2778020697 @default.
• W4310107702 hasConcept C2778461978 @default.
• W4310107702 hasConcept C2779823535 @default.
• W4310107702 hasConcept C2780775027 @default.
• W4310107702 hasConcept C2909962599 @default.
• W4310107702 hasConcept C2911091166 @default.
• W4310107702 hasConcept C71924100 @default.
• W4310107702 hasConcept C87355193 @default.
• W4310107702 hasConceptScore W4310107702C121332964 @default.
• W4310107702 hasConceptScore W4310107702C126322002 @default.
• W4310107702 hasConceptScore W4310107702C142424586 @default.
• W4310107702 hasConceptScore W4310107702C143998085 @default.
• W4310107702 hasConceptScore W4310107702C2776694085 @default.
• W4310107702 hasConceptScore W4310107702C2777408962 @default.
• W4310107702 hasConceptScore W4310107702C2778020697 @default.
• W4310107702 hasConceptScore W4310107702C2778461978 @default.
• W4310107702 hasConceptScore W4310107702C2779823535 @default.
• W4310107702 hasConceptScore W4310107702C2780775027 @default.
• W4310107702 hasConceptScore W4310107702C2909962599 @default.
• W4310107702 hasConceptScore W4310107702C2911091166 @default.
• W4310107702 hasConceptScore W4310107702C71924100 @default.
• W4310107702 hasConceptScore W4310107702C87355193 @default.
• W4310107702 hasIssue "Supplement 1" @default.
• W4310107702 hasLocation W43101077021 @default.
• W4310107702 hasOpenAccess W4310107702 @default.
• W4310107702 hasPrimaryLocation W43101077021 @default.
• W4310107702 hasRelatedWork W1818867749 @default.
• W4310107702 hasRelatedWork W2038414910 @default.
• W4310107702 hasRelatedWork W2546435969 @default.
• W4310107702 hasRelatedWork W2613659662 @default.
• W4310107702 hasRelatedWork W3005187572 @default.
• W4310107702 hasRelatedWork W3030846676 @default.
• W4310107702 hasRelatedWork W3172570903 @default.
• W4310107702 hasRelatedWork W3211002505 @default.

• next